Mechanisms, pathophysiology, and management of obesity

New England Journal of Medicine

Volumn 376, Issue 3, 2017, Pages 254-266

  Heymsfield, Steven B ^a   Wadden, Thomas A ^b  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; LIRAGLUTIDE; LORCASERIN; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; ANTIOBESITY AGENT;

ABDOMINAL PAIN; BACKACHE; BARIATRIC SURGERY; BEHAVIOR THERAPY; BEIGE ADIPOCYTE; BROWN ADIPOCYTE; CALORIC RESTRICTION; CONSTIPATION; COUNSELING; DEFECATION; DEFECATION URGENCY; DIARRHEA; DIZZINESS; DRUG MECHANISM; DYSGEUSIA; ENERGY BALANCE; ENVIRONMENTAL FACTOR; FATIGUE; FECES INCONTINENCE; FLATULENCE; HEADACHE; HEREDITY; HUMAN; HYPOGLYCEMIA; INSOMNIA; LIFESTYLE; NAUSEA; OBESITY; PARESTHESIA; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; ROUX-EN-Y GASTRIC BYPASS; SIDE EFFECT; SLEEVE GASTRECTOMY; SPOTTING; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING; WEIGHT REDUCTION; WHITE ADIPOCYTE; XEROSTOMIA; ADIPOCYTE; BODY MASS; DISEASE MANAGEMENT; GENETICS; HEALTHY LIFESTYLE; LOW CALORY DIET; PHYSIOLOGY;

ADIPOCYTES; ANTI-OBESITY AGENTS; BARIATRIC SURGERY; BODY MASS INDEX; DIET, REDUCING; DISEASE MANAGEMENT; HEALTHY LIFESTYLE; HUMANS; OBESITY; WEIGHT LOSS;

EID: 85010931754     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1514009     Document Type: Review

References (79)

1. Health, United States, 2015: with special feature on racial and ethnic health disparities. Hyattsville, MD: National Center for Health Statistics, 2016: 461.
2. Stecker T, Sparks S. Prevalence of obese patients in a primary care setting. Obesity (Silver Spring) 2006; 14: 373-6.
3. AMA adopts new policies on second day of voting at annual meeting. Press release of the American Medical Association, June 18, 2013 (http://www .npr .org/ documents/ 2013/ jun/ ama-resolution-obesity .pdf).
4. Jones DS, Podolsky SH, Greene JA. The burden of disease and the changing task of medicine. N Engl J Med 2012; 366: 2333-8.
5. Hall KD, Guo J, Dore M, Chow CC. The progressive increase of food waste in America and its environmental impact. PLoS One 2009; 4(11): e7940.
6. Popkin BM, Hawkes C. Sweetening of the global diet, particularly beverages: patterns, trends, and policy responses. Lancet Diabetes Endocrinol 2016; 4: 174-86.
7. Church TS, Thomas DM, Tudor-Locke C, et al. Trends over 5 decades in U.S. occupation-related physical activity and their associations with obesity. PLoS One 2011; 6(5): e19657.
8. von Loeffelholz C. The role of nonexercise activity thermogenesis in human obesity. In: De Groot LJ, ed. Endotext. South Dartmouth, MA: MDText.com, 2000.
9. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342-62.
10. McAllister EJ, Dhurandhar NV, Keith SW, et al. Ten putative contributors to the obesity epidemic. Crit Rev Food Sci Nutr 2009; 49: 868-913.
11. Omran AR. The epidemiologic transition: a theory of the epidemiology of population change. Milbank Mem Fund Q 1971; 49: 509-38.
12. Bray MS, Loos RJ, McCaffery JM, et al. NIH working group report-using genomic information to guide weight management: from universal to precision treatment. Obesity (Silver Spring) 2016; 24: 14-22.
13. Pigeyre M, Yazdi FT, Kaur Y, Meyre D. Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci (Lond) 2016; 130: 943-86.
14. van der Klaauw AA, Farooqi IS. The hunger genes: pathways to obesity. Cell 2015; 161: 119-32.
15. van Dijk SJ, Tellam RL, Morrison JL, Muhlhausler BS, Molloy PL. Recent developments on the role of epigenetics in obesity and metabolic disease. Clin Epigenetics 2015; 7: 66.
16. MacLean PS, Higgins JA, Giles ED, Sherk VD, Jackman MR. The role for adipose tissue in weight regain after weight loss. Obes Rev 2015; 16: Suppl 1: 45-54.
17. Leibel RL, Seeley RJ, Darsow T, Berg EG, Smith SR, Ratner R. Biologic responses to weight loss and weight regain: report from an American Diabetes Association research symposium. Diabetes 2015; 64: 2299-309.
18. Ochner CN, Tsai AG, Kushner RF, Wadden TA. Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. Lancet Diabetes Endocrinol 2015; 3: 232-4.
19. Thomas DM, Bouchard C, Church T, et al. Why do individuals not lose more weight from an exercise intervention at a defined dose? An energy balance analysis. Obes Rev 2012; 13: 835-47.
20. Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev 2014; 15: 310-21.
21. Hall JE, da Silva AA, do Carmo JM, et al. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285: 17271-6.
22. Ferrannini E, Camastra S, Gastaldelli A, et al. Beta-cell function in obesity: effects of weight loss. Diabetes 2004; 53: Suppl 3: S26-S33.
23. Shen W, Wang Z, Punyanita M, et al. Adipose tissue quantification by imaging methods: a proposed classification. Obes Res 2003; 11: 5-16.
24. Tchkonia T, Thomou T, Zhu Y, et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab 2013; 17: 644-56.
25. Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity (Silver Spring) 2015; 23: 512-8.
26. Ashrafian H, Toma T, Rowland SP, et al. Bariatric surgery or non-surgical weight loss for obstructive sleep apnoea? A systematic review and comparison of meta-analyses. Obes Surg 2015; 25: 1239-50.
27. Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23: 471-8.
28. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211.
29. Heymsfield SB, Hu HH, Shen W, Carmichael O. Emerging technologies and their applications in lipid compartment measurement. Trends Endocrinol Metab 2015; 26: 688-98.
30. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8: 521-33.
31. Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014; 2014: 943162.
32. Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004; 23: 6365-78.
33. Berkowitz RI, Fabricatore AN. Obesity, psychiatric status, and psychiatric medications. Psychiatr Clin North Am 2011; 34: 747-64.
34. Wadden TA, Sarwer DB. Behavioral assessment of candidates for bariatric surgery: a patient-oriented approach. Obesity (Silver Spring) 2006; 14: Suppl 2: 53S-62S.
35. Faith MS, Butryn M, Wadden TA, Fabricatore A, Nguyen AM, Heymsfield SB. Evidence for prospective associations among depression and obesity in population- based studies. Obes Rev 2011; 12(5): e438-e453.
36. Hall KD, Sacks G, Chandramohan D, et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378: 826-37.
37. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med 2011; 365: 1597-604.
38. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 2016; 22: Suppl 3: 1-203.
39. American College of Cardiology/ American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Expert Panel Report: guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring) 2014; 22: Suppl 2: S41-410.
40. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601.
41. The Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007; 30: 1374-83.
42. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481-6.
43. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
44. Knowler WC, Fowler SE, Hamman RF, et al. 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374: 1677-86.
45. Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial. JAMA Surg 2015; 150: 931-40.
46. Dixon JB, O'Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316-23.
47. Ikramuddin S, Billington CJ, Lee WJ, et al. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol 2015; 3: 413-22.
48. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-85.
49. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 3-year outcomes. N Engl J Med 2014; 370: 2002-13.
50. Wentworth JM, Playfair J, Laurie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomised controlled trial. Lancet Diabetes Endocrinol 2014; 2: 545-52.
51. Adams TD, Arterburn DE, Nathan DM, Eckel RH. Clinical outcomes of metabolic surgery: microvascular and macrovascular complications. Diabetes Care 2016; 39: 912-23.
52. Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-52.
53. The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-54.
54. Kalarchian MA, King WC, Devlin MJ, et al. Psychiatric disorders and weight change in a prospective study of bariatric surgery patients: a 3-year follow-up. Psychosom Med 2016; 78: 373-81.
55. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013; 159: 758-69.
56. Canadian Obesity Network. 5As Team project. 2016 (http://www .obesitynetwork .ca/ 5As-Team).
57. O'Brien P. Surgical treatment of obesity. In: De Groot LJ, Chrousos G, Dungan K, et al., eds. Endotext. South Dartmouth, MA: MDText.com, January 19, 2016.
58. Teixeira PJ, Silva MN, Coutinho SR, et al. Mediators of weight loss and weight loss maintenance in middle-aged women. Obesity (Silver Spring) 2010; 18: 725-35.
59. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016; 315: 2424-34.
60. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11-22.
61. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1341-52.
62. Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesityrelated risk factors (COR-II). Obesity (Silver Spring) 2013; 21: 935-43.
63. Steinberg DM, Tate DF, Bennett GG, Ennett S, Samuel-Hodge C, Ward DS. The efficacy of a daily self-weighing weight loss intervention using smart scales and e-mail. Obesity (Silver Spring) 2013; 21: 1789-97.
64. Wadden TA, Butryn ML, Hong PS, Tsai AG. Behavioral treatment of obesity in patients encountered in primary care settings: a systematic review. JAMA 2014; 312: 1779-91.
65. Antognoli EL, Seeholzer EL, Gullett H, Jackson B, Smith S, Flocke SA. Primary care resident training for obesity, nutrition, and physical activity counseling: a mixed-methods study. Health Promot Pract 2016 July 08 (Epub ahead of print).
66. Ackermann RT, Liss DT, Finch EA, et al. A randomized comparative effectiveness trial for preventing type 2 diabetes. Am J Public Health 2015; 105: 2328-34.
67. Appel LJ, Clark JM, Yeh H-C, et al. Comparative effectiveness of weight-loss interventions in clinical practice. N Engl J Med 2011; 365: 1959-68.
68. Harvey-Berino J, West D, Krukowski R, et al. Internet delivered behavioral obesity treatment. Prev Med 2010; 51: 123-8.
69. Perri MG, Limacher MC, Durning PE, et al. Extended-care programs for weight management in rural communities: the Treatment of Obesity in Underserved Rural Settings (TOURS) randomized trial. Arch Intern Med 2008; 168: 2347-54.
70. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311: 74-86.
71. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281: 235-42.
72. Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363: 245-56.
73. Sturm R, Hattori A. Morbid obesity rates continue to rise rapidly in the United States. Int J Obes (Lond) 2013; 37: 889-91.
74. Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care 2016; 39: 902-11.
75. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013; 309: 2240-9.
76. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-76.
77. Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361: 445-54.
78. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ 2014; 349: g3961.
79. Puzziferri N, Roshek TB III, Mayo HG, Gallagher R, Belle SH, Livingston EH. Longterm follow-up after bariatric surgery: a systematic review. JAMA 2014; 312: 934-42.